Searchable abstracts of presentations at key conferences in endocrinology

ea0022p49 | Adrenal | ECE2010

In vitro effect of dopastatins on hormone secretion in adrenal tumors

Pivonello Claudia , Napolitano Tiziana , De Leo Monica , Cozzolino Alessia , Vitale Pasquale , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Somatostatin (SSTRs) and dopamine (DRs) receptors are expressed in adrenal tumors. It has been demonstrated in pituitary and neuroendocrine tumors that somatostatin-dopamine chimeric molecules, namely dopastatins, which bind both somatostatin (SST2 and/or SST5) and dopamine (D2) receptors, exert a more potent action compared with the single receptor agonists in experimental settings. The aims of this study were to evaluate the expression of DRs and SSTRs, and the effects of do...

ea0022p657 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Cabergoline treatment in Cushing's disease: effect of cabergoline withdrawal in patients with normalized cortisol secretion after long-term treatment

Pivonello Rosario , De Leo Monica , Cozzolino Alessia , Vitale Pasquale , De Martino Maria Cristina , Simeoli Chiara , Lombardi Gaetano , Colao Annamaria

The dopamine agonist cabergoline has been found to be effective in inducing normalization of cortisol secretion in 25–50% of patients with Cushing’s disease after long-term treatment. Moreover, tumor shrinkage have been documented in selected patients with pituitary corticotroph tumors. The aim of the present study was to evaluate the effect of cabergoline withdrawal in patients with a stable normalization of cortisol secretion and stable or absent visualization of p...

ea0020p26 | Adrenal | ECE2009

Cardiac structure and function in patients with adrenal incidentaloma: an echocardiographic study

De Leo Monica , Galderisi Maurizio , De Martino Maria Cristina , Cozzolino Alessia , Colao Annamaria , Pivonello Rosario , Lombardi Gaetano

Subclinical Cushing’s syndrome (SCS) is a mild autonomous cortisol hypersecretion without specific clinical syndrome of glucocorticoid excess. The aim of this study was to compare cardiac structure and function in patients with adrenal incidentaloma. Twenty patients and 20 sex- and age-matched healthy controls entered the study: among patients, 11 had SCS and the remaining nine had normal cortisol secretion All patients and controls were submitted to Doppler echocardiogra...

ea0020p193 | Endocrine tumours and neoplasia | ECE2009

Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline

Pivonello Rosario , De Leo Monica , De Martino MariaCristina , Cozzolino Alessia , Auriemma Renata S , Galdiero Mariano , Lombardi Gaetano , Colao Annamaria

The first-line treatment of Cushing’s disease is surgery, although it is effective in inducing a long-term remission in around 50% of patients with Cushing’s disease (CD). Nowadays, no pituitary tumor-directed medical treatment is available with the exception of cabergoline, which has been recently demonstrated to control cortisol secretion without major side effects in around 40% of patients with Cushing’s disease. Cabergoline has been recently demonstrated to ...

ea0014oc8.2 | Neuroendocrinology clinical | ECE2007

Effect of GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in acromegalic patients resistant to somatostatin analogues

De Martino Maria Cristina , Auriemma Renata S , Brevetti Gregorio , Galdiero Mariano , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Acromegaly is known to be associated to an increased cardiovascular risk, due to the increased prevalence of glucose intolerance and dyslipidemia and pre-atherosclerotic lesions. The aim of this study was to evaluate the effect of treatment with the GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in patients with acromegaly resistant to somatostatin analogues. Twelve patients (4 m, 8 f, 28–58 yrs) and 24 sex-, age- and BMI-matched controls en...

ea0014p548 | (1) | ECE2007

Effects of combined treatment with cabergoline and somatostatin analogues (SAA) on GH and IGF-I levels and tumor volume in patients with acromegaly not fully responsive to SAA

Auriemma Renata S , Galdiero Mariano , De Martino Maria Cristina , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Dopamine agonists have been used as first or adjunctive therapy for acromegaly for many years, but relatively few studies have assessed the efficacy of a newer agonist, cabergoline (CAB) alone or in combination with somatostatin analogues (SSA). The aim of this study was to evaluate the efficacy of combined treatment with SSA plus CAB in patients with acromegaly and resistance to SSA, defined as lack of normalization of IGF-I levels after long-term (>1 year) and hig...

ea0037ep48 | Adrenal cortex | ECE2015

The treatment with ‘dual release' hydrocortisone (DR-HC) in congenital adrenal hyperplasia: short-term (6 months) and long-term (12 months) follow-up after the switch from conventional glucocorticoids to DR-HC

Simeoli Chiara , De Martino Maria Cristina , Iacuaniello Davide , Mannarino Teresa , Cozzolino Alessia , De Leo Monica , Pivonello Claudia , Negri Mariarosaria , De Angelis Cristina , Colao Annamaria , Pivonello Rosario

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, life-long glucocorticoid (GC) treatment is often required to replace cortisol deficiency and to avoid the ACTH-dependent androgen levels increase. However, in these patients, the multiple daily doses required with conventional GCs can cause cortisol overexposure, leading to an increased risk of metabolic syndrome (MS), an impaired quality of life (QoL), and poor treatment compliance (TC). T...

ea0035p29 | Adrenal cortex | ECE2014

The treatment with glucocorticoids in congenital adrenal hyperplasia: short- and long-term effects of the switch from conventional glucocorticoids to ‘dual release' hydrocortisone on metabolic and hormonal profile

Simeoli Chiara , Mannarino Teresa , De Martino Maria Cristina , Cozzolino Alessia , Iacuaniello Davide , De Leo Monica , Auriemma Renata S , Di Somma Carolina , Colao Annamaria , Pivonello Rosario

Life-long glucocorticoid (GC) treatment is needed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency in order to replace cortisol deficiency and to control ACTH and consequently androgen levels. Therefore, patients with CAH tend to have an increased risk of metabolic syndrome (MS), probably due to cortisol overexposure, caused by multiple daily doses of conventional GCs, unable to mimic cortisol circadian rhythm. The current study aimed at i...

ea0032p21 | Adrenal cortex | ECE2013

Bilateral inferior petrosal sinus sampling in cushing's syndrome: comparison between an old and a new technique in naples experience

De Leo Monica , Tortora Fabio , Cozzolino Alessia , Simeoli Chiara , Iacuaniello Davide , Albano Aurora , Briganti Francesco , Cirillo Sossio , Colao Annamaria , Pivonello Rosario

Introduction: Bilateral inferior petrosal sinus sampling (BIPSS) is the test that offers the highest diagnostic accuracy in the differential diagnosis between pituitary and ectopic Cushng’s syndrome (CS). The aim of this study was to compare the diagnostic accuracy of BIPSS performed in the last six years, after the change in the technical procedure with that performed in the past period in Naples centre.Patients and methods: Seventeen patients with...

ea0032p917 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Effect of short- and long-term treatment with pasireotide on hemochrome in patients with Cushing's disease

Cozzolino Alessia , Simeoli Chiara , Trementino Laura , De Leo Monica , Vitale Pasquale , Iacuaniello Davide , Albano Aurora , Boscaro Marco , Colao Annamaria , Arnaldi Giorgio , Pivonello Rosario

Introduction: Generously supported by IPSEN)-->Glucocorticoids (GC) have a stimulatory effect on neutrophils and an inhibitory effect on the other leukocyte subpopulations. A potential stimulatory effect on erythropoiesis has been also hypothesized. The aim of our study was to evaluate the effect of pasireotide treatment on hemochrome parameters in patients with endogenous pituitary-dependent glucocorticoid excess or Cushing’s d...